The absence of the UGT2B17 gene (UGT2B17null genotype) tended to be associated with an improved survival in female patients compared to carriers of at least one copy of the UGT2B17 gene (median TFS of 254 vs. 126 months; P < 0.10), a difference not observed in men with CLL (Supplementary Material: Supplementary Table 5). Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.